60 Degrees Pharmaceuticals, Inc. (SXTP) AI Stock Analysis

• Market Cap: $5.17M
• Dividend Yield: N/A
• Average Volume (3M): 199.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.03
• Revenue Growth: 192.72%
• EPS Growth: 83.61%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.67
• Shares Outstanding: 4,104,469
• 10 Day Avg. Volume: 488,900
• 30 Day Avg. Volume: 199,179
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.73
• Price to Sales (P/S): 4.83
• P/FCF Ratio: -0.50
• Enterprise Value/Market Cap: 2.16
• Enterprise Value/Revenue: 11.59
• Enterprise Value/Gross Profit: 60.52
• Enterprise Value/Ebitda: -1.41
• 1Y Price Target: $6.00
• Price Target Upside: 506.06% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $1.00 ▲(1.01% Upside)

The overall stock score reflects significant financial and technical challenges. The company's ongoing unprofitability and negative cash flow are major concerns, compounded by bearish technical indicators. The lack of earnings call data and corporate events further limits positive outlook.

Positive Factors

Revenue Growth

The significant year-over-year revenue growth indicates strong demand for the company's products, suggesting potential for future expansion and market penetration.

Improved Equity Position

The improvement in equity position reflects better financial health and reduced reliance on debt, enhancing long-term financial stability.

Product Pipeline Development

Advancements in the product pipeline, such as the Tafenoquine study, indicate ongoing innovation and potential for future revenue streams from new therapies.

Negative Factors

Negative Cash Flow

Persistent negative cash flow from operations suggests challenges in generating sufficient cash internally, which may impact future investment and growth capabilities.

Gross Loss

The gross loss highlights ongoing cost management issues, which could affect profitability and require strategic adjustments to improve margins.

Declining Revenues

The trend of declining revenues over several years indicates potential challenges in market demand or competitive positioning, affecting long-term growth prospects.

60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model

Company Description

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

How the Company Makes Money

60 Degrees Pharmaceuticals generates revenue through the commercialization of its pharmaceutical products, which may include direct sales to healthcare providers and distribution partnerships with pharmaceutical distributors. The company may also derive income from licensing agreements and collaborations with other biopharmaceutical companies, leveraging its research and development capabilities to create valuable intellectual property. Additionally, government grants and funding from research institutions may contribute to its earnings as the company advances its drug development pipeline.

60 Degrees Pharmaceuticals, Inc. Financial Statement Overview

Summary

The company is facing significant financial challenges, with declining revenues, persistent losses, and negative cash flow. Despite some recent improvements in equity and reduced debt, profitability and cash generation remain critical issues.

Income Statement

The company has been experiencing declining revenues, with a significant drop in total revenue from 2020 to 2023. Gross profit margin has been negative in recent years, indicating cost management issues. Net profit margin has been consistently negative, reflecting ongoing unprofitability. Despite some revenue growth in 2024, profitability remains a major concern.

Balance Sheet

The debt-to-equity ratio improved significantly from previous years due to reduced total liabilities, but the company still has challenges with negative equity in past years. In 2024, equity became positive, which is a positive sign. The equity ratio indicates a relatively higher reliance on equity compared to previous years.

Cash Flow

The company has struggled with negative operating cash flow in recent years, indicating challenges with cash generation from core operations. Free cash flow has also been negative, reflecting ongoing investment and financing needs. Positive financing cash flows suggest reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	963.53K	607.57K	253.57K	223.21K	1.16M	2.18M
Gross Profit	184.44K	222.81K	-220.98K	-209.16K	309.60K	1.48M
EBITDA	-7.90M	-7.88M	-1.43M	-2.11M	-1.01M	-341.17K
Net Income	-7.98M	-7.95M	-3.77M	-6.18M	-4.25M	-3.03M
Balance Sheet
Total Assets	6.69M	5.76M	7.78M	1.30M	1.39M	2.61M
Cash, Cash Equivalents and Short-Term Investments	4.12M	3.39M	2.14M	264.87K	115.40K	191.70K
Total Debt	153.76K	155.89K	172.67K	22.42M	18.80M	15.92M
Total Liabilities	2.34M	1.80M	2.99M	25.45M	19.55M	20.68M
Stockholders Equity	4.43M	4.04M	4.87M	-23.58M	-17.58M	-17.50M
Cash Flow
Free Cash Flow	-6.86M	-5.83M	-4.66M	-1.07M	-684.50K	-238.28K
Operating Cash Flow	-6.79M	-5.65M	-4.54M	-1.01M	-649.11K	-167.30K
Investing Cash Flow	1.62M	-1.89M	-115.89K	-60.13K	-35.39K	-70.98K
Financing Cash Flow	5.98M	7.05M	6.47M	1.22M	611.23K	277.36K

60 Degrees Pharmaceuticals, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 0.99 is below the 20-day moving average (MA) of 1.11, below the 50-day MA of 1.33, and below the 200-day MA of 1.84, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 33.68 is Neutral, neither overbought nor oversold. The STOCH value of 52.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.

60 Degrees Pharmaceuticals, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SXTP	38 Underperform	$5.17M	-0.11	-152.19%	―	192.72%	83.61%
ONCO	33 Underperform	$4.76M	>-0.01	-263.57%	―	-34.58%	96.41%
KALA	31 Underperform	$5.28M	-0.11	―	―	―	52.39%
OGEN	29 Underperform	$4.66M	-0.04	-168.95%	―	―	90.27%

60 Degrees Pharmaceuticals, Inc. Corporate Events

60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth Efforts

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and marketing new medicines for infectious diseases, with its lead product, ARAKODA, approved for malaria prevention. The company recently released its earnings report for the quarter ended September 30, 2025, highlighting both financial challenges and strategic developments.

60 Degrees Pharmaceuticals Advances Tafenoquine Study for Chronic Babesiosis

Study Overview: The B-FREE Chronic Babesiosis Study, officially titled B-FREE Chronic Babesiosis Study: A Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients With Severe Fatigue, aims to evaluate the efficacy of Tafenoquine in treating chronic babesiosis, particularly in patients suffering from severe fatigue. This study is significant as it addresses a debilitating condition with limited treatment options.

60 Degrees Pharmaceuticals Holds Annual Stockholders Meeting

On October 8, 2025, 60 Degrees Pharmaceuticals, Inc. held its virtual 2025 Annual Stockholders Meeting, where various proposals were voted on by the shareholders. The meeting saw the election of five directors, approval of an amendment to increase shares in the 2022 Equity Incentive Plan, a reverse stock split, and the ratification of RBSM LLP as the accounting firm for 2025, all of which were approved.

The most recent analyst rating on (SXTP) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.

60 Degrees Pharmaceuticals Highlights ARAKODA Growth Potential

On September 9, 2025, 60 Degrees Pharmaceuticals, Inc. presented investor information highlighting the potential growth of ARAKODA, especially for chronic babesiosis, which could surpass its use for malaria prevention. The company faces challenges such as low brand recognition and competition from generic alternatives, but aims to address these through a commercial pilot program to increase awareness and differentiate ARAKODA in the market.

The most recent analyst rating on (SXTP) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.

60 Degrees Pharmaceuticals Enters New Sales Agreement

On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. entered into an At-The-Market Sales Agreement with H.C. Wainwright & Co., LLC to offer and sell shares of its common stock, potentially raising up to $1,397,533. The agreement allows the company flexibility in selling shares while Wainwright acts as the sales agent, earning a 3% commission on sales. Additionally, on the same date, the company terminated a previous sales agreement with Wallachbeth Capital LLC, effective immediately, releasing both parties from any obligations.

The most recent analyst rating on (SXTP) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.